ReproNovo
ReproNovo is a biotech company in Lausanne, Switzerland, founded in 2021. It has raised $62.0M across 1 round, most recently a $62.0M Series A in May 2025.
- Headquarters
- Lausanne
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- repronovo.com
- Total Funding
- $62.0M
- Last Round
- $62.0M Series AMay 2025
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round for this company. The full record is or through the API.
About
ReproNovo is a biopharmaceutical company developing innovative therapeutic solutions for reproductive medicine and women's health, including male and female infertility and uterine conditions like adenomyosis. Founded in 2021 and headquartered in Lausanne, Switzerland, the company has two Phase 2 clinical-stage assets: RPN-001 (leflutrozole) for male infertility and RPN-002 (nolasiban) for adenomyosis management and improved IVF outcomes.
Summary
It lists 11–50 employees. It has raised $62.0M in total across 1 round, most recently a $62.0M Series A round in May 2025.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
May 2025
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/repronovo"><img src="https://indexed.vc/api/badge/company/repronovo" alt="ReproNovo on Indexed.vc" width="260" height="76" /></a>